PT217

DB18472InvestigationalProtein Based Therapies

PT217 is a bispecific Antibody against DLL3 and CD47.

Mechanism: Pharmacologically active on Leukocyte surface antigen CD47 and Delta-like protein 3
Curator reviewed
Code names: PT-217

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with PT217, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.